Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Clinical trial NCT02951156 · TERMINATED
Trial details
- NCT number
- NCT02951156
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-16
- Primary completion
- 2019-12-02
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.